Genus (GNS) 44th Annual J.P. Morgan Healthcare Conference Presentation summary

Leadership and vision

• CEO Jorgen Kokke appointed in July 2023, bringing extensive international food and agriculture experience.

• Anand Date joined as Investor Relations & Sustainability Director in September 2023, with a strong financial background.

• Vision centers on pioneering animal genetic improvement to sustainably nourish the world.

Business model and operations

• Produces and sells elite animal genetics, representing less than 2% of a farmer's cost base.

• Focuses on traits like feed conversion, growth rates, and robustness to improve animal health and protein yield.

• Drives continuous genetic improvement using phenotypic and genomic scoring, with top animals bred for next generations.

• Pioneers precision gene editing to address major disease challenges in animal protein production.

Market position and financials

• Global #1 in porcine genetics (PIC) and #2 in bovine genetics (ABS), with strong recurring royalty revenue models.

• Royalty revenue model ensures high customer retention, decouples profit from commodity prices, and underpins profit growth.

• Adjusted operating profit has grown at a 6.2% CAGR, with return on adjusted invested capital rising to 14.7%.

• Over 10% of revenue invested in R&D, focusing on genetic improvement and breakthrough technologies.